Safety check for advanced breast cancer combo in indian patients
NCT ID NCT05631795
Summary
This study checked the safety of a two-drug combination (alpelisib and fulvestrant) for people in India with advanced breast cancer that has a specific genetic change (PIK3CA mutation) and has worsened after hormone therapy. It involved 40 men and post-menopausal women. The main goal was to see how many participants experienced side effects from the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Guwahati, Assam, 781016, India
-
Novartis Investigative Site
Surat, Gujarat, 395009, India
-
Novartis Investigative Site
Thalassery, Kerala, 670103, India
-
Novartis Investigative Site
Trivandrum, Kerala, 695 011, India
-
Novartis Investigative Site
Bhopal, Madhya Pradesh, 462001, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400 012, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 440001, India
-
Novartis Investigative Site
Pune, Maharashtra, 411040, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110029, India
-
Novartis Investigative Site
Hyderabad, Telangana, 500004, India
-
Novartis Investigative Site
Ahmedabad, 380016, India
-
Novartis Investigative Site
Kolkata, 700026, India
Conditions
Explore the condition pages connected to this study.